Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Leukemia, Myeloid, Acute: early-phase trial registry
10 of 31 indexed Leukemia, Myeloid, Acute trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #495 of 28,707 conditions by registered trial count.
31 US clinical trials · 10 currently recruiting · #495 of 28,707 conditions by registered trial count
Leukemia, Myeloid, Acute: 31 US clinical trials tracked, 10 recruiting.
Leukemia, Myeloid, Acute is the subject of 31 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 23 in Phase 1-2 (earlier-stage). The most active sponsor is Washington University School of Medicine, running 4 of these trials.
Enrollment posture brief
Registry condition leukemia-myeloid-acute
OPEN 10 | RECR 32% | LATE 3 | EARLY 23 | RANK #495 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Hypertension (32% recruiting · 472 trials)
Leukemia, Myeloid, Acute lists 10 open slots (32% of 31 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Leukemia, Myeloid, Acute on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Leukemia, Myeloid, Acute is recruiting below its size-band peers.
10 of 31 indexed trials (32.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Leukemia, Myeloid, Acute trials is spread across many organizations.
Washington University School of Medicine accounts for 4 of 31 trials (12.9%). 23 distinct sponsors appear on at least one study for this condition label.
-
Typical Leukemia, Myeloid, Acute enrolment sits around 80 participants.
Median target enrolment is 80 among the 31 trials that report a genuine target (sentinel values excluded). 17 of those (54.8%) plan for fewer than 100 participants.
-
Leukemia, Myeloid, Acute research is mostly interventional.
28 interventional and 3 observational studies make up this index (90.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
31 total, page 1 of 1
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Janssen Research & Development
NCT06852222
A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation
Sumitomo Pharma America
NCT04988555
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Aptose Biosciences
NCT03850574
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Kura Oncology
NCT06001788
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
BlossomHill Therapeutics
NCT06501196
A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
OncoVerity
NCT06384261
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Orca Biosystems
NCT07216443
Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML
Wake Forest University Health Sciences
NCT06580106
DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
Delta-Fly Pharma
NCT06382168
CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML
University of Pennsylvania
NCT05945849
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
Janssen Research & Development
NCT05453903
Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
Actinium Pharmaceuticals
NCT02665065
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
Institut de Recherches Internationales Servier
NCT03173248
A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
Celgene
NCT02677922
Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia
OncoVerity
NCT04150887
Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation
University of Miami
NCT05968963
An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)
Celgene
NCT02775903
An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)
Millennium Pharmaceuticals
NCT02610777
Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
Washington University School of Medicine
NCT01687400
Use of Saline-Washed Platelet and Red Cell Transfusions in Adult Acute Leukemia
University of Rochester
NCT01976442
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
Washington University School of Medicine
NCT00241358
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
Medical College of Wisconsin
NCT00849147
A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-World
Pfizer
NCT04337138
Azacitidine and Lenalidomide for Acute Myeloid Leukemia
Washington University School of Medicine
NCT01016600
A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission
CSL Limited
NCT01632852
Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid Leukemia
Weill Medical College of Cornell University
NCT03335267
Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant
Washington University School of Medicine
NCT00986804
Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Indiana University School of Medicine
NCT00875745
CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome
Weill Medical College of Cornell University
NCT03393611
Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation
National Heart, Lung, and Blood Institute (NHLBI)
NCT00859586
A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)
Celgene
NCT04887857
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 16 |
| Phase 2 | 7 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Leukemia, Myeloid, Acute records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Leukemia, Myeloid, Acute trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Leukemia, Myeloid, Acute page
31 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 10 Leukemia, Myeloid, Acute trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Washington University School of Medicine sponsors the most Leukemia, Myeloid, Acute trials on record, review their full trial history before evaluating a specific study. See Washington University School of Medicine's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Leukemia, Myeloid, Acute condition card totals 31 registered trials; most-linked intervention Azacitidine; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.